glp 1 agonist in ckd Design and discovery of a highly potent ultralong-acting GLP-1 and glucagon co-agonist for attenuating renal fibrosis CKJ REVIEW GLP-1 receptor agonists
Description
D.AmarJ.IglesiasM
Front Endocrinol (Lausanne) 2022;13:1007980
[DOI] [PubMed] [Google Scholar] 11.Struck E., Ashmore J., Wieland O
Two interventions have a strong evidence base and should, in my view, be part of every GLP-1 treatment discussion
however, emerging evidence suggests that the effects extend beyond metabolic regulation
